CLPT -
ClearPoint Neuro, Inc. Common Stock
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 13.4 0.42 (3.16%) |
-0.01 (-0.05%) |
-0.03 (-0.19%) |
-0.16 (-1.12%) |
0.29 (2.15%) |
0.35 (2.62%) |
-0.01 (-0.07%) |
0.17 (1.24%) |
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.
Earnings & Ratios
- Basic EPS:
- -0.21
- Diluted EPS:
- -0.21
- Basic P/E:
- -65.8238
- Diluted P/E:
- -65.8238
- RSI(14) 1m:
- 41.4
- VWAP:
- 13.83
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
Global MRI Guided Neurosurgical Ablation Market Poised for Steady Growth, Projected to Reach USD 227.56 Million by 2034 Driven by Growing Adoption and Advancements in Non-Cooled Laser Systems: FMI
Nov 20, 2024 09:30
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial
Jun 20, 2024 12:45
ClearPoint's (CLPT) New Products to Boost Neurosurgical Segment
Jun 03, 2024 15:53
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
Jun 01, 2024 13:00
Does ClearPoint Neuro (CLPT) Have the Potential to Rally 81.49% as Wall Street Analysts Expect?
May 29, 2024 13:55
Wall Street Analysts Predict a 70.65% Upside in ClearPoint Neuro (CLPT): Here's What You Should Know
May 13, 2024 13:55
Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates
May 03, 2024 12:10
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates
May 02, 2024 21:30
ClearPoint Neuro félicite son partenaire AviadoBio pour son premier patient traité dans le cadre de son essai clinique ASPIRE-FTD évaluant l’AVB-101 dans la démence fronto-temporale avec mutations du gène GRN
Apr 17, 2024 19:21
ClearPoint Neuro beglückwünscht seinem Partner AviadoBio zur Behandlung des ersten Patienten in der klinischen Studie ASPIRE-FTD, in der AVB-101 für frontotemporale Demenz mit GRN-Mutationen evaluiert wird
Apr 17, 2024 19:21